Ellis Named to Houston Business Journal’s 40 Under 40 Class of 2020
25 August 2020
Houston Business Journal
Partner Scott Ellis has been named to the Houston Business Journal’s 40 Under 40 Class of 2020.
Ellis is vice chair of Foley’s national Energy Litigation Practice and the hiring partner for the firm’s Houston office.
The class is made up of business and community leaders under 40 who live in the Houston metropolitan area. A panel of judges scored the nominees on the basis of leadership, overcoming challenges and community involvement.
Honorees will be recognized in the journal’s Oct. 30 weekly edition and celebrated during a live broadcast on Oct. 29.
Ellis is vice chair of Foley’s national Energy Litigation Practice and the hiring partner for the firm’s Houston office.
The class is made up of business and community leaders under 40 who live in the Houston metropolitan area. A panel of judges scored the nominees on the basis of leadership, overcoming challenges and community involvement.
Honorees will be recognized in the journal’s Oct. 30 weekly edition and celebrated during a live broadcast on Oct. 29.
People
Related News
10 October 2024
In the News
Christopher King Highlights M&A Due Diligence Considerations
Foley & Lardner LLP partner Christopher King's comments on M&A due diligence at the Association of Corporate Counsel's annual meeting were highlighted in the Legal Dive article, "Can this marriage work? Legal tips for corporate M&A."
09 October 2024
In the News
Jason Mehta Weighs in on SEC Settlements, Clinical Research Fraud
Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”
08 October 2024
In the News
John Strom Assesses BIOSECURE ACT – 'Going to be tough to navigate'
Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."